131 related articles for article (PubMed ID: 15128047)
1. Effects of CYP2C9 polymorphisms on the pharmacokinetics of R- and S-phenprocoumon in healthy volunteers.
Kirchheiner J; Ufer M; Walter EC; Kammerer B; Kahlich R; Meisel C; Schwab M; Gleiter CH; Rane A; Roots I; Brockmöller J
Pharmacogenetics; 2004 Jan; 14(1):19-26. PubMed ID: 15128047
[TBL] [Abstract][Full Text] [Related]
2. Genetic polymorphisms of cytochrome P450 2C9 causing reduced phenprocoumon (S)-7-hydroxylation in vitro and in vivo.
Ufer M; Kammerer B; Kahlich R; Kirchheiner J; Yasar U; Brockmöller J; Rane A
Xenobiotica; 2004 Sep; 34(9):847-59. PubMed ID: 15742978
[TBL] [Abstract][Full Text] [Related]
3. Stereospecific pharmacokinetic characterisation of phenprocoumon metabolites, and mass-spectrometric identification of two novel metabolites in human plasma and liver microsomes.
Kammerer B; Kahlich R; Ufer M; Schenkel A; Laufer S; Gleiter CH
Anal Bioanal Chem; 2005 Nov; 383(6):909-17. PubMed ID: 16237546
[TBL] [Abstract][Full Text] [Related]
4. Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol.
Ufer M
Clin Pharmacokinet; 2005; 44(12):1227-46. PubMed ID: 16372822
[TBL] [Abstract][Full Text] [Related]
5. Influence of CYP2C9 genetic polymorphisms on pharmacokinetics of celecoxib and its metabolites.
Kirchheiner J; Störmer E; Meisel C; Steinbach N; Roots I; Brockmöller J
Pharmacogenetics; 2003 Aug; 13(8):473-80. PubMed ID: 12893985
[TBL] [Abstract][Full Text] [Related]
6. Effects of cytochrome P450 2C9 polymorphisms on phenprocoumon anticoagulation status.
Schalekamp T; Oosterhof M; van Meegen E; van Der Meer FJ; Conemans J; Hermans M; Meijerman I; de Boer A
Clin Pharmacol Ther; 2004 Nov; 76(5):409-17. PubMed ID: 15536456
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenetic differences between warfarin, acenocoumarol and phenprocoumon.
Beinema M; Brouwers JR; Schalekamp T; Wilffert B
Thromb Haemost; 2008 Dec; 100(6):1052-7. PubMed ID: 19132230
[TBL] [Abstract][Full Text] [Related]
8. VKORC1 and CYP2C9 genotypes and phenprocoumon anticoagulation status: interaction between both genotypes affects dose requirement.
Schalekamp T; Brassé BP; Roijers JF; van Meegen E; van der Meer FJ; van Wijk EM; Egberts AC; de Boer A
Clin Pharmacol Ther; 2007 Feb; 81(2):185-93. PubMed ID: 17192772
[TBL] [Abstract][Full Text] [Related]
9. The risk of overanticoagulation in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon.
Visser LE; van Vliet M; van Schaik RH; Kasbergen AA; De Smet PA; Vulto AG; Hofman A; van Duijn CM; Stricker BH
Pharmacogenetics; 2004 Jan; 14(1):27-33. PubMed ID: 15128048
[TBL] [Abstract][Full Text] [Related]
10. Influence of CYP2C9 and CYP2D6 polymorphisms on the pharmacokinetics of nateglinide in genotyped healthy volunteers.
Kirchheiner J; Meineke I; Müller G; Bauer S; Rohde W; Meisel C; Roots I; Brockmöller J
Clin Pharmacokinet; 2004; 43(4):267-78. PubMed ID: 15005635
[TBL] [Abstract][Full Text] [Related]
11. Quantifying the effect of covariates on concentrations and effects of steady-state phenprocoumon using a population pharmacokinetic/pharmacodynamic model.
Abduljalil K; Lazar S; Natanzon M; Wu W; Zadoyan G; Steffens B; Kohl V; Mörike K; Tomalik-Scharte D; Stingl J; Schwab M; Harenberg J; Gleiter C; Fuhr U
Clin Pharmacokinet; 2013 May; 52(5):359-71. PubMed ID: 23519598
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2: no relationship to the CYP2C9 genetic polymorphism in humans.
Kirchheiner J; Meineke I; Steinbach N; Meisel C; Roots I; Brockmöller J
Br J Clin Pharmacol; 2003 Jan; 55(1):51-61. PubMed ID: 12534640
[TBL] [Abstract][Full Text] [Related]
13. CYP2C9 polymorphisms and the interindividual variability in pharmacokinetics and pharmacodynamics of the loop diuretic drug torsemide.
Vormfelde SV; Engelhardt S; Zirk A; Meineke I; Tuchen F; Kirchheiner J; Brockmöller J
Clin Pharmacol Ther; 2004 Dec; 76(6):557-66. PubMed ID: 15592327
[TBL] [Abstract][Full Text] [Related]
14. Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers.
Kirchheiner J; Brockmöller J; Meineke I; Bauer S; Rohde W; Meisel C; Roots I
Clin Pharmacol Ther; 2002 Apr; 71(4):286-96. PubMed ID: 11956512
[TBL] [Abstract][Full Text] [Related]
15. Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers.
Kirchheiner J; Kudlicz D; Meisel C; Bauer S; Meineke I; Roots I; Brockmöller J
Clin Pharmacol Ther; 2003 Aug; 74(2):186-94. PubMed ID: 12891229
[TBL] [Abstract][Full Text] [Related]
16. Altered pharmacokinetics of R- and S-acenocoumarol in a subject heterozygous for CYP2C9*3.
Thijssen HH; Drittij MJ; Vervoort LM; de Vries-Hanje JC
Clin Pharmacol Ther; 2001 Sep; 70(3):292-8. PubMed ID: 11557918
[TBL] [Abstract][Full Text] [Related]
17. The risk of bleeding complications in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon.
Visser LE; van Schaik RH; van Vliet M; Trienekens PH; De Smet PA; Vulto AG; Hofman A; van Duijn CM; Stricker BH
Thromb Haemost; 2004 Jul; 92(1):61-6. PubMed ID: 15213846
[TBL] [Abstract][Full Text] [Related]
18. Roles of two allelic variants (Arg144Cys and Ile359Leu) of cytochrome P4502C9 in the oxidation of tolbutamide and warfarin by human liver microsomes.
Yamazaki H; Inoue K; Shimada T
Xenobiotica; 1998 Feb; 28(2):103-15. PubMed ID: 9522436
[TBL] [Abstract][Full Text] [Related]
19. Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers.
Kirchheiner J; Bauer S; Meineke I; Rohde W; Prang V; Meisel C; Roots I; Brockmöller J
Pharmacogenetics; 2002 Mar; 12(2):101-9. PubMed ID: 11875364
[TBL] [Abstract][Full Text] [Related]
20. Acenocoumarol pharmacokinetics in relation to cytochrome P450 2C9 genotype.
Thijssen HH; Ritzen B
Clin Pharmacol Ther; 2003 Jul; 74(1):61-8. PubMed ID: 12844136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]